Central Pacific Bank Trust Division Has $1.53 Million Position in Zimmer Biomet Holdings, Inc. (NYSE:ZBH)

Central Pacific Bank Trust Division increased its position in shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 7.4% during the fourth quarter, Holdings Channel reports. The institutional investor owned 14,525 shares of the medical equipment provider’s stock after purchasing an additional 1,000 shares during the quarter. Central Pacific Bank Trust Division’s holdings in Zimmer Biomet were worth $1,534,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors and hedge funds have also modified their holdings of the company. Dunhill Financial LLC boosted its holdings in Zimmer Biomet by 1,090.0% during the third quarter. Dunhill Financial LLC now owns 238 shares of the medical equipment provider’s stock valued at $26,000 after purchasing an additional 218 shares in the last quarter. Ashton Thomas Securities LLC bought a new stake in Zimmer Biomet during the third quarter worth about $28,000. Bangor Savings Bank acquired a new stake in shares of Zimmer Biomet during the third quarter worth approximately $31,000. Brooklyn Investment Group bought a new position in shares of Zimmer Biomet in the third quarter valued at approximately $35,000. Finally, Quarry LP acquired a new position in shares of Zimmer Biomet in the 2nd quarter worth approximately $53,000. 88.89% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

Several equities analysts have issued reports on the company. TD Cowen cut their price objective on Zimmer Biomet from $143.00 to $119.00 and set a “hold” rating for the company in a research report on Friday, September 6th. JPMorgan Chase & Co. upgraded shares of Zimmer Biomet from a “neutral” rating to an “overweight” rating and upped their price target for the stock from $125.00 to $128.00 in a research report on Tuesday, December 17th. Wolfe Research assumed coverage on shares of Zimmer Biomet in a research note on Tuesday, September 10th. They issued a “peer perform” rating for the company. Truist Financial raised their price target on shares of Zimmer Biomet from $117.00 to $118.00 and gave the company a “hold” rating in a report on Wednesday, December 18th. Finally, BTIG Research reduced their price objective on Zimmer Biomet from $134.00 to $126.00 and set a “buy” rating on the stock in a report on Thursday, October 3rd. Two analysts have rated the stock with a sell rating, eleven have given a hold rating and eight have given a buy rating to the stock. According to data from MarketBeat.com, Zimmer Biomet currently has a consensus rating of “Hold” and an average price target of $123.33.

Zimmer Biomet Trading Down 0.5 %

Shares of NYSE ZBH traded down $0.48 during midday trading on Friday, reaching $103.98. 516,760 shares of the stock were exchanged, compared to its average volume of 665,956. The company has a debt-to-equity ratio of 0.38, a current ratio of 1.36 and a quick ratio of 0.70. Zimmer Biomet Holdings, Inc. has a 12 month low of $101.47 and a 12 month high of $133.90. The business has a 50-day simple moving average of $108.33 and a two-hundred day simple moving average of $108.19. The company has a market capitalization of $20.70 billion, a price-to-earnings ratio of 19.77, a P/E/G ratio of 1.96 and a beta of 1.02.

Zimmer Biomet (NYSE:ZBH) last announced its quarterly earnings results on Wednesday, October 30th. The medical equipment provider reported $1.74 earnings per share (EPS) for the quarter, hitting the consensus estimate of $1.74. Zimmer Biomet had a return on equity of 12.95% and a net margin of 14.27%. The company had revenue of $1.82 billion during the quarter, compared to the consensus estimate of $1.80 billion. During the same period in the prior year, the company earned $1.65 earnings per share. The company’s revenue for the quarter was up 4.1% compared to the same quarter last year. As a group, equities research analysts expect that Zimmer Biomet Holdings, Inc. will post 7.99 EPS for the current year.

Zimmer Biomet Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Friday, January 31st. Stockholders of record on Monday, December 30th will be given a dividend of $0.24 per share. This represents a $0.96 annualized dividend and a dividend yield of 0.92%. The ex-dividend date of this dividend is Monday, December 30th. Zimmer Biomet’s dividend payout ratio is 18.25%.

Zimmer Biomet Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.